On March 28, CR Sanjiu published the Annual Report for 2012. According to the report, during the reporting period, the company realized a total operating income of CNY 6.89 billion, a year-on-year increase of 24.72%, a net profit of CNY 1.01 billion was returned to shareholders of the listed company, a year-on-year increase of 33.35% and a basic earning per share of CNY 1.04. According to a bulletin from CR Sanjiu, the company intends to distribute CNY 2.60 for every 10 shares (including tax) and a total of CNY 254 million will be distributed in cash.

The report shows that the business performance of CR Sanjiu exceeded expectation and realized a breakthrough growth in 2012, thanks mainly to the steady growth of OTC business and soaring growth of the prescription drug business. In 2012, the OTC business of CR Sanjiu saw a growth of 16%. Of all OTC drugs, sales of medicine for cold, Shun Feng skin drugs, Qiangli Pipa Lu, Qizhiweitong Particles, medicine for pediatric cold grew rapidly while drugs for gastrointestinal illnesses saw a steady growth. The prescription drug business saw a growth of 51%. Of all prescription drugs, sales of its core products, namely Shenfu Injection, Huachansu Injection and Xintailin Injection (Cefazolin Sodium Pentahydrate for Injection), as well as Yinzhihuang Oral Solution, a new product, saw a soaring growth, Shuxuening injection saw a satisfactory growth and the antibiotics business saw a recovery growth, while particles of various Chinese medicine formulations saw a limited growth, due to the limited production capacity.